| Name | Title | Contact Details |
|---|
Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn`s disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction.
Protoms Radiance 330 Proton Therapy System is compact, customizable, and has the industrys fastest return on investment.
Kyowa Hakko Kirin Pharma is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Through the use of telepsychiatry technology, we’re able to help our partner facilities see patients more efficiently and in a wide variety of locations.
Vireo Health, Inc. a physician-led multi-state medical cannabis company, is committed to safely alleviating pain by providing patients with best-in-class cannabis products and compassionate care.